List of Aemcolo drug patents

Aemcolo is owned by Redhill.

Aemcolo contains Rifamycin Sodium.

Aemcolo has a total of 4 drug patents out of which 0 drug patents have expired.

Aemcolo was authorised for market use on 16 November, 2018.

Aemcolo is available in tablet, delayed release;oral dosage forms.

Aemcolo can be used as treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults.

Drug patent challenges can be filed against Aemcolo from November, 2027.

The generics of Aemcolo are possible to be released after 16 November, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 16, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic